Address
25 West Watkins Mill Road
Redwood City, MD 20878
United States of America (the)
Phone
240 327 0603
Website
Sector
Healthcare
Industry
Biotechnology
Employees
163
First IPO Date
February 04, 2022
| Name | Title | Pay | Year Born |
| Rami Elghandour | Chairman of the Board, Chief Executive Officer & President | 1.38M | 1979 |
| Neeraj Teotia | Chief Commercial Officer | 461,949 | 1975 |
| Christopher R. Heery | Chief Medical Officer | 794,520 | 1981 |
| Michelle Lim Gilson | Chief Financial Officer | 878,017 | 1993 |
| Heba Nowyhed | Chief Scientific Officer | 0 | N/A |
| Helen Kim | VP & Head of Regulatory Affairs | 0 | N/A |
| Kate Aiken | Chief People Officer | 0 | N/A |
| Myesha Lacy | Chief Investor & Communications Officer | 0 | N/A |
| Narinderjeet Singh | Chief Technical Officer | 0 | 1972 |
| Aileen Fernandes | Chief Operating Officer | 0 | N/A |
| Maryam Abdul-Kareem | General Counsel & Chief Legal Officer | 0 | N/A |
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.